US20060013782A1 - Use of active extracts to improve the appearance of skin, lips, hair and/or nails - Google Patents

Use of active extracts to improve the appearance of skin, lips, hair and/or nails Download PDF

Info

Publication number
US20060013782A1
US20060013782A1 US11/155,359 US15535905A US2006013782A1 US 20060013782 A1 US20060013782 A1 US 20060013782A1 US 15535905 A US15535905 A US 15535905A US 2006013782 A1 US2006013782 A1 US 2006013782A1
Authority
US
United States
Prior art keywords
composition
skin
lips
nails
hair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/155,359
Inventor
Harish Mahalingam
Brian Jones
Nicole McCain
Pornngarm Limtrakul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avon Products Inc
Original Assignee
Avon Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Products Inc filed Critical Avon Products Inc
Priority to US11/155,359 priority Critical patent/US20060013782A1/en
Assigned to AVON PRODUCTS, INC. reassignment AVON PRODUCTS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MCCAIN, NICOLE, JONES, BRIAN C., MAHALINGAM, HARISH, LIMTRAKUL, PORNNGARM
Publication of US20060013782A1 publication Critical patent/US20060013782A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11Pteridophyta or Filicophyta (ferns)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/58Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • A61K36/746Morinda
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9741Pteridophyta [ferns]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/08Preparations for bleaching the hair

Definitions

  • the present invention relates to topical compositions having an active ingredient naturally or synthetically derived from a plant or plant material. More particularly, the present invention relates to topical compositions that improve the appearance of skin, lips, hair and/or nails, especially by lightening the skin, lips, hair, and/or nails. Most particularly, the present invention relates to biologically active extracts for improving the aesthetic appearance of, especially by lightening, the skin, lips, hair, and/or nails.
  • Skin, hair, lip and nail pigmentation is determined by the level of melanin present in the epidermis, hair fiber and nail bed.
  • Three different types of melanin are present in the epidermis: DHI-melanin, DHICA-melanin and pheomelanin.
  • the different types of melanin vary in color or shade. DHI-melanin is the darkest, and is blackish in color.
  • DHICA-melanin is brownish in color.
  • Pheomelanin is the lightest, and is reddish in color.
  • Melanin is synthesized in specialized organelles called melanosomes within pigment-producing cells (melanocytes). Melanocytes respond to stimuli to regulate melanin synthesis.
  • Perilla extract is disclosed as a whitening agent in U.S. Pat. No. 5,980,904 and Japanese Publications Nos. 07025742, 07187989, 10265322, 2001163759, and 2001181173.
  • coconut fruit extract is disclosed as a whitening agent in Japanese Patent No. 2896815B2.
  • An extract of the spongy mass of coconut tissue is employed in a tanning sunscreen composition in U.S. Pat. No. 5,756,099.
  • Active ingredients derived from plants and plant seeds have been employed in topical compositions for a myriad of medicinal, therapeutic and cosmetic purposes.
  • Such active ingredients can be obtained from various parts of a plant such as seeds, needles, leaves, roots, bark, cones, stems, rhizomes, callus cells, protoplasts, organs and organ systems, and meristems.
  • Such active ingredients are incorporated in such compositions in a variety of forms.
  • Such forms include a pure or semi-pure component, a solid or liquid extract or derivative, or a solid plant matter. Plant matter may be incorporated in a variety of subforms such as whole, minced, ground or crushed.
  • Extracts of Azadirachta indica are known to have insecticidal activity.
  • Azadirachtin a major active ingredient of many of these extracts, is a liminoid of the tetranortriterpenoid type useful in commercial insecticides. Tetranortriterpenoids have been shown to be a potent insect growth regulator and feeding deterrent.
  • Methods for producing azadirachtin concentrates from neem seed materials are known in the art.
  • U.S. Pat. No. 5,698,423 to Holowach-Keller et al. is directed to a method for producing azadiractin by cell culture of Azadiracta indica.
  • Extracts of Glycyrrhiza glabra linn are derived from the herb, which grows perennially in subtropical and warm temperate regions.
  • Glycyrrhiza glabra linn . commonly known as licorice, has been used in food sweetening.
  • the root extract contains glycyrrhizic acid and glycyrrhetinic acid.
  • the glycyrrhizic acid is known to have an anti-inflammatory effect.
  • the extract of the licorice root and glycyrrhetinic acid have been shown to have desoxycorticosterone and ACTH-like effects. It has been used as a demulcent and mild expectorant.
  • Extracts of Morinda citrifolia are derived from the Indian Mulberry plant.
  • Morinda citrifolia has been used in compositions for reducing oxysterol buildup in the blood and normalizing cholesterol and blood pressure in mammals as set forth in U.S. Pat. No. 6,387,370 to Yegorova.
  • a method of extracting and purifying an essential oil product of Morinda citrifolia is disclosed in U.S. Pat. No. 6,417,157 to Wadsworth et al.
  • Extracts of tomato glycolipid are derived from tomato fruit. Methods of extracting and synthesizing tomato glycolipids are disclosed in U.S. Pat. No. 4,745,186 to Mudd et al.
  • Butea frondosa also known as Butea monosperma
  • Butea frondosa has been used as an astringent and in treating diarrhea, dysentery, and pyrosis.
  • Use of Butea frondosa for its ocular anti-inflammatory activity has recently been tested (See Mengi, “Evaluation of Ocular Anti-Inflammatory Activity of Butea frondosa ,” Ind. J. Pharma. 27, 116-119 (1995)).
  • Extracts of Naringi crenulata also known as Limonia crenulata , are derived from a small tree indigenous to East India.
  • Stenoloma chusana is a perennial herb found in southeast Asia. Extracts from this plant are known to have uses in treating colds, influenza, bronchitis, burns, cuts, and skin sores (See A Barefoot Doctor's Manual, Running Press, Philadelphia, Pa., p. 638).
  • compositions that employ new biological extracts that provide an improved aesthetic appearance to the skin, lips, hair and/or nails especially that provide effective levels of lightening, bleaching, hypopigmenting, whitening and/or depigmenting (hereinafter referred to individually and collectively as “lightening” or “lighten”). It would further be desirable to have compositions that are effective in lightening hair, skin, lips, and/or nails and require minimal concentrations of the biological material.
  • compositions for lightening of hair, skin, lips, and/or nails having an active plant extract, preferably an active biological plant extract.
  • compositions for improving the appearance, especially by lightening, of hair, skin, lips, and/or nails in which such compositions are suitable for topical application to the hair, skin, lips, and/or nails.
  • compositions for improving the appearance, especially by lightening, of hair, skin, lips, and/or nails or by reducing, preventing, or treating inflammation of the skin or lips, including inflammation occasioned by ailment, affliction or disease of the skin or lips, or inflammation induced or inducible by an external agent in which such compositions have an effective amount of at least one of the following active extracts: Butea frondosa, Naringi crenulata, Stenoloma chusana , or any combinations thereof.
  • compositions for improving the appearance, especially by lightening, of skin, lips, hair and/or nails or by reducing, preventing, or treating inflammation of the skin or lips, including inflammation occasioned by ailment, affliction or disease of the skin or lips, or induced or inducible by an external agent in which such compositions have an effective amount of at least one of the active extracts, and an effective amount of at least one of the following additional extracts: Azadirachta indica, Glycyrrhiza glabra Linn., Morinda citrifolia , tomato glycolipid, or any combinations thereof.
  • the present invention also provides methods for improving the appearance, especially by lightening, of hair, skin, lips, and/or nails or by reducing, preventing, or treating inflammation of the skin or lips, including inflammation occasioned by ailment, affliction or disease of the skin or lips, or induced or inducible by an external agent, comprising topically applying any one of the compositions of the present invention.
  • the present invention also provides methods for lightening hair, skin, lips, and/or nails by orally ingesting any one of the compositions of the present invention.
  • the present invention provides compositions for improving the appearance of hair, skin, lips, and/or nails, especially by lightening hair, skin, lips, and/or nails.
  • the compositions are preferably topical compositions for application to the hair, skin, lips, and/or nails.
  • the present compositions can be for oral ingestion. In all applications, the compositions result in a lightening of the hair, skin, lips and/or nails.
  • the compositions of the present invention also provide an anti-inflammatory benefit when applied to skin or lips, so that the appearance of skin is improved.
  • compositions have one or more of the following extracts, as an active biological plant extract or ingredient(s) or in an active amount: Butea frondosa, Naringi crenulata, Stenoloma chusana , or any combinations thereof. It has been unexpectedly found that these active extracts improve the aesthetic appearance of hair, skin, lips and/or nails and, in particular, reduce pigmentation and lighten hair, skin, lips, and/or nails. More particularly, these active extracts have been unexpectedly shown to decrease melanin production and decrease hypermelanocytic states.
  • Lightening of hair, skin, lips and/or nails means one or more of the following benefits is achieved. These benefits include bleaching hyperpigmented hair, skin, lips, and/or nails; reducing age spots; evening or optimizing skin discoloration; improving the appearance of dark circles under the eyes; treating melasma, cholasma, freckles, after-burn scars, and post-injury hyperpigmentation; bleaching hair on the scalp, legs, face, and other areas where bleaching and color reduction are desired; and bleaching nail stains.
  • the present invention also provides topical compositions containing an effective amount of one or more of the active ingredients of the present invention for application to the skin to improve the aesthetic appearance of skin.
  • These benefits are manifest in any of the following: reduction in pore size; improvement in skin tone, radiance, clarity and/or tautness; promotion of anti-oxidant activity; improvement in skin firmness, plumpness, suppleness, and/or softness; improvement in procollagen and/or collagen production; improvement in skin texture and/or promotion of retexturization; improvement in skin barrier repair and/or function; improvement in appearance of skin contours; restoration of skin luster and/or brightness; replenishment of essential nutrients and/or constituents in the skin decreased by aging and/or menopause; improvement in communication among skin cells; increase in cell proliferation and/or multiplication; increase in skin cell metabolism decreased by aging and/or menopause; improvement in skin moisturization; promotion and/or acceleration of cell turnover; enhancement of skin thickness; reducing skin sensitivity; increase in skin elasticity and/or resiliency;
  • the present invention also provides for topical compositions for application to the skin that provide an anti-aging benefit.
  • the compositions have an effective amount of one or more active ingredients of the present invention, which, when applied to human skin, prevent, treat and/or ameliorate the various signs of aging at the area or portion of skin to which they are applied.
  • the present invention provides compositions and methods for treating skin to prevent, inhibit, reduce and/or ameliorate the signs of dermatological aging due to, for example, chronological aging, hormonal aging, and/or photoaging.
  • Such signs of aging include, but are not limited to skin fragility; loss of collagen and/or elastin; estrogen imbalance in skin; skin atrophy; appearance and/or depth of lines and/or wrinkles, including fine lines; skin discoloration, including dark eye circles; skin sagging; skin fatigue and/or stress, e.g., skin breakout due to environmental stress, such as pollution and/or temperature changes; skin dryness; skin flakiness; cellular aging; loss of skin tone, elasticity and/or luster; loss of skin firmness; poor skin texture; loss of skin elasticity and/or resiliency; and thin skin.
  • the present invention is not limited by any particular characterization of the physiological and/or chemical effects of the active extract or agents.
  • the active extract used in the present compositions and methods are believed to reduce melanin in hyperpigmented areas by decreasing dark pigment formation in melanocytes and shifting the melanin synthesis path towards light melanin formation by decreasing melanocyte pH, and/or direct chelation of metals involved in melanin synthesis or staining, for example, copper.
  • the topically applied compositions of the present invention inhibit, mitigate, ameliorate, and prevent skin and lip irritation or inflammation occasioned by ailment, illness or disease, or induced by external factors such as environmental agents, chemical agents, medicinal agents and cosmetic agents.
  • Skin irritation thus may result from exposure to wind, heat or cold, air pollutants, and cigarette smoke.
  • Cosmetic and pharmaceutical products may have ingredients or combinations of ingredients that produce visible skin irritation as a side effect. Susceptibility to skin irritation may vary from individual to individual, and frequently limits the use of certain products or the use of concentrations of active ingredients that might produce more advantageous results at higher levels but for the production of skin irritation as a side-effect.
  • Skin irritation symptoms or conditions include, but are not limited to, erythema, psoriasis, edema, hyper-pigmentation, hypo-pigmentation, acne, warts, wheeling, blotchiness, uneven skin tone, scaling, flaking, itching or pruritus, tightness, burning, prickling, stinging, tingling, numbing, wind irritation, temperature irritation, smoke irritation, chemical irritation, or any combinations thereof.
  • the method of the present invention provides that an effective amount from about 0.001 wt % to about 20 wt % by weight of the composition, is effective in the treatment of one or more of the following: reducing or preventing loss of collagen; improving skin firmness/plumpness; improving skin texture; decreasing/preventing lines and wrinkles; improving skin tone; enhancing skin thickness; decreasing pore size; reducing skin discoloration; reducing acne; reducing psoriasis; reducing skin sensitivity; and reducing warts.
  • Cosmetic, dermatological and pharmaceutical products commonly have an active agent or agents that produce skin irritation.
  • active agents having skin irritation as a side effect include, but are not limited to, hydroxylated acids and their derivatives, ⁇ -hydroxy acids (i.e., lactic, glycolic, citric, malic, tartaric, mandelic, gluconic, methyl lactic, phenyl lactic, atrolactic, glyceric, benzilic, z-hydroxyheptanoic, z-hydroxyoctanoic and any combinations thereof), ⁇ -hydroxy acids (i.e., salicylic, 5-n-octanoylsalicylic and other derivatives of salicylic), retinoids (retinoic acid and its derivatives; retinol and its esters); anthralins (i.e., dioxyanthranol), anthranoids, peroxides (i.e., benzoyl peroxide), minoxidil, lithium salts, antimetabolites,
  • topical products had anti-irritant protection, it would be possible to increase the amount of the normal irritant active agent (i.e., AHA or BHA) in the product without producing unpleasant skin irritation or irritation side effects.
  • AHA or BHA normal irritant active agent
  • the use of the present compositions makes it possible to improve the efficacy of cosmetic, dermatological or pharmaceutical products by increasing the concentration or amount of cosmetic, dermatological, or pharmaceutical active agent as compared to the amount or concentration of such agent normally used.
  • the composition which improves the appearance of and, in particular, lightens hair, skin, lips, and/or nails, has an effective amount of at least one of the following active extracts: Butea frondosa, Naringi crenulata, Stenoloma chusana , or any combinations thereof.
  • An effective amount means that the one or more active extracts are present at about 0.001 percentage by weight (wt %) to about 20 wt % based on the total weight of the composition.
  • the one or more active extracts are present preferably at about 0.05 wt % to about 10 wt %, and more preferably at about 0.5 wt % to about 5 wt %, based on the total weight of the composition. Most preferably, the one or more active extracts are present in an amount about 1 wt % or less based on the total weight of the composition.
  • the composition for lightening hair, skin, lips, and/or nails has an effective amount of at least one of the active extracts, and one or more of the following other or additional extracts: Azadirachta indica, Glycyrrhiza glabra linn., Morinda citrifolia , tomato glycolipid, or any combinations thereof, to synergistically enhance the whitening activity of the composition.
  • the one or more of the additional extracts are present in an amount about 0.05 wt % to about 10 wt % based on the total weight of the composition. Preferably, the one or more additional extracts in an amount about 0.5 wt % to about 5 wt % based on the total weight of the composition. Most preferably, the one or more additional extracts are present in an amount equal to or less than 1 wt % based on the total weight of the composition.
  • the active extracts When combined with one or more of the additional extracts, the active extracts are present in the present compositions in an amount about 0.001 wt % to about 10 wt %, and the one or more additional extracts in an amount about 0.05 wt % to about 10 wt %, based on the total weight of the composition.
  • the active extracts are present in an amount about 0.05 wt % to about 10 wt %, and the one or more additional extracts in an amount about 0.5 wt % to about 5 wt % based on the total weight of the composition.
  • the one or more active extracts are present in an amount equal to or less than about 1 wt %, and the one or more additional extracts are present in an amount equal to or less than 1 wt %, based on the total weight of the composition.
  • compositions of the present invention can be used with a carrier or vehicle.
  • vehicle can be altered to be appropriate for the specific use of the composition without altering the beneficial lightening effects achieved by the use of the one or more active extracts set forth above.
  • the vehicles that can be used in compositions of the present invention include, but are not limited to, water; vegetable oils; esters such as octyl palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dicapryl ether and dimethyl isosorbide; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, stearyl alcohol and behenyl alcohol; isoparaffins such as isooctane, isododecane and isohexadecane; silicone oils such as dimethicones and polysiloxanes; hydrocarbon oils such as mineral oil, petrolatum, isoeicosane and polyisobutene; polyols such as prop
  • the vehicle is present in an amount about 50 wt % to about 99.8 wt % based on the total weight of the composition. More preferably, the vehicle is present in an amount about 80 wt % to about 99.5 wt % based on the total weight of the composition.
  • compositions may also include one or more of the following ingredients: anesthetic, anti-allergenic, antifungal, antimicrobial, anti-inflammatory agent, antioxidant, antiseptic, chelating agent, colorant, depigmenting agent, emollient, emulsifier, exfollient, film former, fragrance, humectant, insect repellent, lubricant, moisturizer, pharmaceutical agent, photostabilizing agent, preservative, skin protectant, skin penetration enhancer, sunscreen, stabilizer, surfactant, thickener, viscosity modifier, vitamin, or any combinations thereof.
  • these ingredients are present in an amount about 0.001 wt % to about 10 wt % based on the total weight of the composition.
  • compositions may also include skin whiteners.
  • suitable skin whiteners include, but are not limited to, one or more of the following: ascorbyl glucoside, vitamin C, retinol and/or its derivatives, arbutin, bearberry extract, rumex crispus extract, milk proteins including hydrolyzed milk proteins, N,N,S-tris(carboxymethyl)cysteamine, oleanolic acids, perilla oils, placenta extract, saxifragia sarmentosa, perilla extract, juniperic acid, TDPA, ligusticum chiangxiong hort., asmunda japonica thunb., stellaria medica (L.) cyr., sedum sarmentosum bunge, ligusticum lucidum Ait., ilex purpurea hassk , emblica, apigenin, ascorbyl palmitol, carruba polyphenol
  • compositions of the present invention can be formulated in any suitable product form.
  • product forms include, but are not limited to, aerosol spray, cream, dispersion, emulsion, foam, gel, liquid, lotion, mousse, ointment, patch, pomade, powder, pump spray, solid, solution, stick, and towelette.
  • compositions provide for products, especially cosmetic products that improve lightening of skin, nail, lips, and/or hair. Also, the present compositions can be formulated to deliver a consistent level of an active ingredient, or blend of ingredients, so that a desired cosmetic effect is achieved.
  • Melanosome Uptake Assay Stenolama Chusana and Naringi Crenulata was done as follows. Confluent cultures of B16 melanocytes produce moderate levels of melanosomes. However, to induce elevated melanosome production in this cell line, semi-confluent (60%) cultures of B16 cells were treated for approximately thirty-six (36) hours with normal growth medium supplemented with 10 mM ammonium chloride (final conc.). The medium was then aspirated and the hypermelanotic cells were washed (2 ⁇ 2 ml) with distilled water to provide a hypotonic stress to the cells.
  • the treatment of keratinocytes with melanosomes was measured as follows.
  • the normal human epidermal keratinocytes (NHEKs) (available from Clonetics, Inc.) were plated in the wells of 24-well plates at a density of 200,000 cells/well. Approximately twenty-four (24) hours later, the growth medium was replaced with 1 ml of the appropriate growth medium (i.e., DMEM/KGM-2) containing the melanosome preparation with or without additional treatment conditions.
  • the cells were treated with different concentrations of perilla leaf extract (powder form or aqueous form). The cells were then returned to the incubator for approximately one and one-half (1.5) hours.
  • each well of keratinocytes was treated with the amount of melanosomes isolated from a single plate of B16 cells.
  • the 24-well plates of treated keratinocytes were centrifuged for 15 minutes at 1,000 rpm to facilitate the deposition of the melanosomes onto the surface membranes of the keratinocytes. The plates were then returned to the incubator for 1.25 hours.
  • the cells in each well of keratinocytes were rinsed (3 ⁇ 1 ml) with PBS, removed from the plate using trypsin/EDTA, and washed with PBS.
  • the internalized melanin was extracted from the cells according to a modified method of Bessou-Touya, S., et al. (Chimeric human epidermal reconstructs to study the role of melanocytes and keratinocytes in pigmentation and photoprotection. J. Invest. Dermatol., 111:1103-1108, 1998) and quantified spectrophoto-metrically by determining the melanin-specific absorbance at 405 nm.
  • the melanocytes synthesize melanin and deposits onto melanosomes.
  • Visual manifestation of skin color is due to presence of melanin/melanosomes in keratinocytes.
  • Melanosomes are taken up by keratinocytes and the rate of uptake, retention and processing of melanosomes in the keratinocytes is a key determinant of skin color.
  • the internalized melanin value reflects the amount of melanin/melanosome uptake and retention by the keratinocytes.
  • the lower internalized melanin values particularly internalized melanin values that are less than the control with melanin, indicate that melanin uptake by the keratinocytes has been inhibited.
  • B16 assay Naringi Crenulata
  • B16 assay Naringi Crenulata
  • the actives were tested in monolayer cell culture of B16 mouse melanoma cells. These cells constitutively produce melanin and are a model system for monitoring the inhibition of melanin synthesis.
  • the cells were seeded into 96-well plates at 5 ⁇ 10 3 cells/well and culture attached for twenty-four (24) hours. The media were then replaced with fresh media containing plant extracts.
  • Each active was applied to six (6) wells of B16 cells on 96-well plates to allow statistical analysis.
  • the cells were dosed with medium alone as the negative control, or the test article for seven (7) days.
  • the plates were read at 540 nM to detect melanin formation. An increase in absorbance at 540 nM reflects a higher melanin content in the well.
  • Naringi Crenulata showed a 61% decrease in pigmentation as compared to the positive control
  • melanogenic activity was measured by measuring the radioactive melanin formed as 14 C DOPA is converted to the acid insoluble melanin biopolymer in B16F10 melanoma cells.
  • Cells were seeded into 24-well plates at a density of 2 ⁇ 10 4 cells per well and cultured attached for forty-eight (48) hours. The media were then replaced with fresh media containing plant extracts and 0.2 ⁇ Ci of 14 C DOPA. The cells were further incubated for 24 hours. After incubation, media were discarded and the cells were rinsed with PBS, lysed by adding 0.125 ml of 1N NaOH and incubated at 37° C.
  • Butea frondosa showed a 22% decrease in 14 C DOPA conversion as compared to the positive control.
  • This assay employed the quantitative sandwich enzyme immunoassay technique in which a monoclonal antibody specific for TNF-alpha has been pre-coated onto a microtiter plate.
  • Culture supernatants from cells exposed to active materials were pipetted into separate wells. TNF-alpha in the supernatant was bound to the plate via the immobilized antibody. After several washes to remove unbound antibody, an enzyme-linked polyclonal antibody specific for TNF-alpha was added to each well. Following a wash to remove unbound antibody-enzyme reagent, a substrate solution was added to the wells. Color develops in proportion to the amount of TNF-alpha bound in the initial step. The results of the tests are provided in Table I.
  • compositions of the present invention containing an extract of: Stenolama chusana Ching., Naringi Crenulata , and Butea frondosa Roxb . provide benefits to the skin by inhibiting TNF-alpha protein production, whereby the signs of subjective discomfort and/or irritation caused by cosmetic, pharmaceutical or dermatological products would be reduced, thus providing an aesthetic improvement in skin appearance.
  • Stenolama chusana ching were evaluated in various biopsy studies in which the natural plant extract as set forth below was incorporated into a cosmetically suitable vehicle and applied to the volar forearm of a participant in the study, at a dose of 2 mg/cm 2 .
  • the forearm area to which the extract preparation was applied was then covered with a semi-occlusive patch. This procedure was repeated for 3 weeks, 5 days per week.
  • the sites were anesthetized with lidocaine and 2 mm punch biopsies were taken from the treated and one untreated control site. Biopsies were fixed in formalin, embedded in paraffin, sectioned, and stained for relevant endpoints.

Abstract

There is provided a composition having at least one of the following active extracts Butea frondosa, Naringi crenulata, Stenoloma chusana, or any combinations thereof. There is also provided a composition having at least one of the following additional extracts Azadirachta indica, Glycyrrhiza glabra linn., Morinda citrifolia, tomato glycolipid or any combinations thereof in combination with one or more of the active extracts. The compositions and methods of the invention are effective to improve the aesthetic appearance of skin, lips, hair and/or nails, especially by lightening the skin, lips, hair and/or nails.

Description

    RELATED APPLICATIONS
  • This is a continuation-in-part application that claims priority to, and the benefits of, co-pending U.S. patent application Ser. No. 10/321,706, filed Dec. 17, 2002.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to topical compositions having an active ingredient naturally or synthetically derived from a plant or plant material. More particularly, the present invention relates to topical compositions that improve the appearance of skin, lips, hair and/or nails, especially by lightening the skin, lips, hair, and/or nails. Most particularly, the present invention relates to biologically active extracts for improving the aesthetic appearance of, especially by lightening, the skin, lips, hair, and/or nails.
  • 2. Description of the Related Art
  • Consumers constantly seek to improve the appearance of their hair, skin, lips and nails. There is a need for products that effectively lighten and reduce pigmentation in the hair, skin, lips and nails. Common applications for such products include, for example, bleaching hyperpigmented hair, skin, lips and/or nails; reducing age spots; evening or optimizing skin discoloration; improving the appearance of dark circles under the eyes; treating melasma, cholasma, freckles, after-burn scars, and post-injury hyperpigmentation; bleaching hair on the scalp, legs, face, and other areas where bleaching and color reduction are desired; and bleaching nail stains.
  • Skin, hair, lip and nail pigmentation is determined by the level of melanin present in the epidermis, hair fiber and nail bed. Three different types of melanin are present in the epidermis: DHI-melanin, DHICA-melanin and pheomelanin. The different types of melanin vary in color or shade. DHI-melanin is the darkest, and is blackish in color. DHICA-melanin is brownish in color. Pheomelanin is the lightest, and is reddish in color.
  • Melanin is synthesized in specialized organelles called melanosomes within pigment-producing cells (melanocytes). Melanocytes respond to stimuli to regulate melanin synthesis.
  • Many substances have been applied to the skin to lighten the skin. Such substances include hydroquinone, kojic acid, licorice and/or its derivatives, ascorbic acid and/or its derivatives, arbutin, bearberry, Glycyrrhiza glabra and its derivatives, Chlorella vulgaris extract, perilla extract, and coconut fruit extract. Perilla extract is disclosed as a whitening agent in U.S. Pat. No. 5,980,904 and Japanese Publications Nos. 07025742, 07187989, 10265322, 2001163759, and 2001181173. Coconut fruit extract is disclosed as a whitening agent in Japanese Patent No. 2896815B2. An extract of the spongy mass of coconut tissue is employed in a tanning sunscreen composition in U.S. Pat. No. 5,756,099.
  • Active ingredients derived from plants and plant seeds have been employed in topical compositions for a myriad of medicinal, therapeutic and cosmetic purposes. Such active ingredients can be obtained from various parts of a plant such as seeds, needles, leaves, roots, bark, cones, stems, rhizomes, callus cells, protoplasts, organs and organ systems, and meristems. Such active ingredients are incorporated in such compositions in a variety of forms. Such forms include a pure or semi-pure component, a solid or liquid extract or derivative, or a solid plant matter. Plant matter may be incorporated in a variety of subforms such as whole, minced, ground or crushed.
  • Extracts of Azadirachta indica, the neem tree, as well as other plants in the family Meliaceae, are known to have insecticidal activity. Azadirachtin, a major active ingredient of many of these extracts, is a liminoid of the tetranortriterpenoid type useful in commercial insecticides. Tetranortriterpenoids have been shown to be a potent insect growth regulator and feeding deterrent. Methods for producing azadirachtin concentrates from neem seed materials are known in the art. U.S. Pat. No. 5,698,423 to Holowach-Keller et al. is directed to a method for producing azadiractin by cell culture of Azadiracta indica.
  • Extracts of Glycyrrhiza glabra linn. are derived from the herb, which grows perennially in subtropical and warm temperate regions. Glycyrrhiza glabra linn., commonly known as licorice, has been used in food sweetening. The root extract contains glycyrrhizic acid and glycyrrhetinic acid. The glycyrrhizic acid is known to have an anti-inflammatory effect. The extract of the licorice root and glycyrrhetinic acid have been shown to have desoxycorticosterone and ACTH-like effects. It has been used as a demulcent and mild expectorant. In vitro studies have shown the antiviral properties of both glycyrrhetinic acid and glycyrrhizin (See Badam, “In Vitro Studies on the Effect of Glycyrrhizin from Glycyrrhiza glabra linn. on Some RNA and DNA Viruses,” Ind. J. Pharma., 26, 194-199 (1994)). The extracts of Glycyrrhiza glabra linn. can be extracted by a method disclosed in U.S. Pat. No. 6,248,309 to Iyer, et al.
  • Extracts of Morinda citrifolia are derived from the Indian Mulberry plant. Morinda citrifolia has been used in compositions for reducing oxysterol buildup in the blood and normalizing cholesterol and blood pressure in mammals as set forth in U.S. Pat. No. 6,387,370 to Yegorova. A method of extracting and purifying an essential oil product of Morinda citrifolia is disclosed in U.S. Pat. No. 6,417,157 to Wadsworth et al.
  • Extracts of tomato glycolipid are derived from tomato fruit. Methods of extracting and synthesizing tomato glycolipids are disclosed in U.S. Pat. No. 4,745,186 to Mudd et al.
  • Extracts of Butea frondosa, also known as Butea monosperma, are derived from an East Indian deciduous tree. Butea frondosa has been used as an astringent and in treating diarrhea, dysentery, and pyrosis. Use of Butea frondosa for its ocular anti-inflammatory activity has recently been tested (See Mengi, “Evaluation of Ocular Anti-Inflammatory Activity of Butea frondosa,” Ind. J. Pharma. 27, 116-119 (1995)).
  • Extracts of Naringi crenulata, also known as Limonia crenulata, are derived from a small tree indigenous to East India.
  • Stenoloma chusana is a perennial herb found in southeast Asia. Extracts from this plant are known to have uses in treating colds, influenza, bronchitis, burns, cuts, and skin sores (See A Barefoot Doctor's Manual, Running Press, Philadelphia, Pa., p. 638).
  • Heretofore, these extracts have not been used as an active ingredient in a composition for the purpose of lightening skin, lips, hair or nails.
  • It would be desirable to have compositions that employ new biological extracts that provide an improved aesthetic appearance to the skin, lips, hair and/or nails, especially that provide effective levels of lightening, bleaching, hypopigmenting, whitening and/or depigmenting (hereinafter referred to individually and collectively as “lightening” or “lighten”). It would further be desirable to have compositions that are effective in lightening hair, skin, lips, and/or nails and require minimal concentrations of the biological material.
  • SUMMARY OF THE INVENTION
  • It is an object of the present invention to provide cosmetic compositions that improve the aesthetic appearance of skin, lips, hair and/or nails including remediating the effects of aging.
  • It is another object of the present invention to provide compositions for lightening of hair, skin, lips, and/or nails having an active plant extract, preferably an active biological plant extract.
  • It is yet another object of the present invention to provide such compositions for improving the appearance, especially by lightening, of skin, lips, hair and/or nails in which the compositions having an effective amount of an active plant extract.
  • It is still another object of the present invention to provide such compositions for improving the appearance, especially by lightening, of hair, skin, lips, and/or nails, in which such compositions are suitable for topical application to the hair, skin, lips, and/or nails.
  • It is still yet another object of the present invention to provide such compositions for improving the appearance of skin and lips by ameliorating inflammation of the skin and/or lips, including inflammation induced by or capable of inducement by external agents.
  • It is a further object of the present invention to provide compositions for lightening hair, skin, lips, and/or nails that is suitable for oral ingestion.
  • It is a still further object of the present invention to provide methods of lightening hair, skin, lips, and/or nails that include topically applying such compositions to hair, skin, lips and/or nails.
  • These and other objects and advantages of the present invention are provided by compositions for improving the appearance, especially by lightening, of hair, skin, lips, and/or nails or by reducing, preventing, or treating inflammation of the skin or lips, including inflammation occasioned by ailment, affliction or disease of the skin or lips, or inflammation induced or inducible by an external agent, in which such compositions have an effective amount of at least one of the following active extracts: Butea frondosa, Naringi crenulata, Stenoloma chusana, or any combinations thereof.
  • There is also provided compositions for improving the appearance, especially by lightening, of skin, lips, hair and/or nails or by reducing, preventing, or treating inflammation of the skin or lips, including inflammation occasioned by ailment, affliction or disease of the skin or lips, or induced or inducible by an external agent, in which such compositions have an effective amount of at least one of the active extracts, and an effective amount of at least one of the following additional extracts: Azadirachta indica, Glycyrrhiza glabra Linn., Morinda citrifolia, tomato glycolipid, or any combinations thereof.
  • The present invention also provides methods for improving the appearance, especially by lightening, of hair, skin, lips, and/or nails or by reducing, preventing, or treating inflammation of the skin or lips, including inflammation occasioned by ailment, affliction or disease of the skin or lips, or induced or inducible by an external agent, comprising topically applying any one of the compositions of the present invention. The present invention also provides methods for lightening hair, skin, lips, and/or nails by orally ingesting any one of the compositions of the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides compositions for improving the appearance of hair, skin, lips, and/or nails, especially by lightening hair, skin, lips, and/or nails. The compositions are preferably topical compositions for application to the hair, skin, lips, and/or nails. However, the present compositions can be for oral ingestion. In all applications, the compositions result in a lightening of the hair, skin, lips and/or nails. The compositions of the present invention also provide an anti-inflammatory benefit when applied to skin or lips, so that the appearance of skin is improved.
  • The compositions have one or more of the following extracts, as an active biological plant extract or ingredient(s) or in an active amount: Butea frondosa, Naringi crenulata, Stenoloma chusana, or any combinations thereof. It has been unexpectedly found that these active extracts improve the aesthetic appearance of hair, skin, lips and/or nails and, in particular, reduce pigmentation and lighten hair, skin, lips, and/or nails. More particularly, these active extracts have been unexpectedly shown to decrease melanin production and decrease hypermelanocytic states.
  • It has now been also found that the addition of at least one of these active extracts, namely Butea frondosa, Naringi crenulata, Stenoloma chusana, or any combinations thereof, to at least one of the following other or additional extracts, namely Azadirachta indica, Glycyrrhiza glabra linn., Morinda citrifolia, tomato glycolipid, or any combinations thereof, can reduce melanin pigmentation of hair, skin, lips and/or nails.
  • Lightening of hair, skin, lips and/or nails, as used in the present invention, means one or more of the following benefits is achieved. These benefits include bleaching hyperpigmented hair, skin, lips, and/or nails; reducing age spots; evening or optimizing skin discoloration; improving the appearance of dark circles under the eyes; treating melasma, cholasma, freckles, after-burn scars, and post-injury hyperpigmentation; bleaching hair on the scalp, legs, face, and other areas where bleaching and color reduction are desired; and bleaching nail stains.
  • Most generally, the present invention also provides topical compositions containing an effective amount of one or more of the active ingredients of the present invention for application to the skin to improve the aesthetic appearance of skin. These benefits are manifest in any of the following: reduction in pore size; improvement in skin tone, radiance, clarity and/or tautness; promotion of anti-oxidant activity; improvement in skin firmness, plumpness, suppleness, and/or softness; improvement in procollagen and/or collagen production; improvement in skin texture and/or promotion of retexturization; improvement in skin barrier repair and/or function; improvement in appearance of skin contours; restoration of skin luster and/or brightness; replenishment of essential nutrients and/or constituents in the skin decreased by aging and/or menopause; improvement in communication among skin cells; increase in cell proliferation and/or multiplication; increase in skin cell metabolism decreased by aging and/or menopause; improvement in skin moisturization; promotion and/or acceleration of cell turnover; enhancement of skin thickness; reducing skin sensitivity; increase in skin elasticity and/or resiliency; and enhancement of exfoliation, with or without the use of alpha or beta hydroxy acids, keto acids or other exfoliants.
  • Collaterally, the present invention also provides for topical compositions for application to the skin that provide an anti-aging benefit. The compositions have an effective amount of one or more active ingredients of the present invention, which, when applied to human skin, prevent, treat and/or ameliorate the various signs of aging at the area or portion of skin to which they are applied. In particular, the present invention provides compositions and methods for treating skin to prevent, inhibit, reduce and/or ameliorate the signs of dermatological aging due to, for example, chronological aging, hormonal aging, and/or photoaging. Such signs of aging include, but are not limited to skin fragility; loss of collagen and/or elastin; estrogen imbalance in skin; skin atrophy; appearance and/or depth of lines and/or wrinkles, including fine lines; skin discoloration, including dark eye circles; skin sagging; skin fatigue and/or stress, e.g., skin breakout due to environmental stress, such as pollution and/or temperature changes; skin dryness; skin flakiness; cellular aging; loss of skin tone, elasticity and/or luster; loss of skin firmness; poor skin texture; loss of skin elasticity and/or resiliency; and thin skin.
  • In its broadest aspects, the present invention is not limited by any particular characterization of the physiological and/or chemical effects of the active extract or agents. However, the active extract used in the present compositions and methods are believed to reduce melanin in hyperpigmented areas by decreasing dark pigment formation in melanocytes and shifting the melanin synthesis path towards light melanin formation by decreasing melanocyte pH, and/or direct chelation of metals involved in melanin synthesis or staining, for example, copper.
  • In another aspect of the present invention, the topically applied compositions of the present invention inhibit, mitigate, ameliorate, and prevent skin and lip irritation or inflammation occasioned by ailment, illness or disease, or induced by external factors such as environmental agents, chemical agents, medicinal agents and cosmetic agents. Skin irritation thus may result from exposure to wind, heat or cold, air pollutants, and cigarette smoke. Cosmetic and pharmaceutical products may have ingredients or combinations of ingredients that produce visible skin irritation as a side effect. Susceptibility to skin irritation may vary from individual to individual, and frequently limits the use of certain products or the use of concentrations of active ingredients that might produce more advantageous results at higher levels but for the production of skin irritation as a side-effect. Skin irritation symptoms or conditions include, but are not limited to, erythema, psoriasis, edema, hyper-pigmentation, hypo-pigmentation, acne, warts, wheeling, blotchiness, uneven skin tone, scaling, flaking, itching or pruritus, tightness, burning, prickling, stinging, tingling, numbing, wind irritation, temperature irritation, smoke irritation, chemical irritation, or any combinations thereof. Accordingly, the method of the present invention provides that an effective amount from about 0.001 wt % to about 20 wt % by weight of the composition, is effective in the treatment of one or more of the following: reducing or preventing loss of collagen; improving skin firmness/plumpness; improving skin texture; decreasing/preventing lines and wrinkles; improving skin tone; enhancing skin thickness; decreasing pore size; reducing skin discoloration; reducing acne; reducing psoriasis; reducing skin sensitivity; and reducing warts.
  • Cosmetic, dermatological and pharmaceutical products commonly have an active agent or agents that produce skin irritation. Examples of active agents having skin irritation as a side effect include, but are not limited to, hydroxylated acids and their derivatives, α-hydroxy acids (i.e., lactic, glycolic, citric, malic, tartaric, mandelic, gluconic, methyl lactic, phenyl lactic, atrolactic, glyceric, benzilic, z-hydroxyheptanoic, z-hydroxyoctanoic and any combinations thereof), β-hydroxy acids (i.e., salicylic, 5-n-octanoylsalicylic and other derivatives of salicylic), retinoids (retinoic acid and its derivatives; retinol and its esters); anthralins (i.e., dioxyanthranol), anthranoids, peroxides (i.e., benzoyl peroxide), minoxidil, lithium salts, antimetabolites, vitamin D and its derivatives, hair dyes or colorants (i.e., para-phenylenediamine and its derivatives; aminophenols), alcoholic perfuming solutions (i.e., perfumes; toilet waters; aftershaves; deodorants), antiperspirant agents (i.e., some aluminum salts), depilatory or hair permanent active agents (i.e., thiols), depigmentating agents (i.e., hydroquinone), and some insecticide active agents. If topical products had anti-irritant protection, it would be possible to increase the amount of the normal irritant active agent (i.e., AHA or BHA) in the product without producing unpleasant skin irritation or irritation side effects. The use of the present compositions makes it possible to improve the efficacy of cosmetic, dermatological or pharmaceutical products by increasing the concentration or amount of cosmetic, dermatological, or pharmaceutical active agent as compared to the amount or concentration of such agent normally used.
  • In a preferred embodiment of the present invention, the composition, which improves the appearance of and, in particular, lightens hair, skin, lips, and/or nails, has an effective amount of at least one of the following active extracts: Butea frondosa, Naringi crenulata, Stenoloma chusana, or any combinations thereof. An effective amount means that the one or more active extracts are present at about 0.001 percentage by weight (wt %) to about 20 wt % based on the total weight of the composition. The one or more active extracts are present preferably at about 0.05 wt % to about 10 wt %, and more preferably at about 0.5 wt % to about 5 wt %, based on the total weight of the composition. Most preferably, the one or more active extracts are present in an amount about 1 wt % or less based on the total weight of the composition.
  • As stated above, in another preferred embodiment of the present invention, the composition for lightening hair, skin, lips, and/or nails has an effective amount of at least one of the active extracts, and one or more of the following other or additional extracts: Azadirachta indica, Glycyrrhiza glabra linn., Morinda citrifolia, tomato glycolipid, or any combinations thereof, to synergistically enhance the whitening activity of the composition.
  • The one or more of the additional extracts are present in an amount about 0.05 wt % to about 10 wt % based on the total weight of the composition. Preferably, the one or more additional extracts in an amount about 0.5 wt % to about 5 wt % based on the total weight of the composition. Most preferably, the one or more additional extracts are present in an amount equal to or less than 1 wt % based on the total weight of the composition.
  • When combined with one or more of the additional extracts, the active extracts are present in the present compositions in an amount about 0.001 wt % to about 10 wt %, and the one or more additional extracts in an amount about 0.05 wt % to about 10 wt %, based on the total weight of the composition. Preferably, the active extracts are present in an amount about 0.05 wt % to about 10 wt %, and the one or more additional extracts in an amount about 0.5 wt % to about 5 wt % based on the total weight of the composition. Most preferably, the one or more active extracts are present in an amount equal to or less than about 1 wt %, and the one or more additional extracts are present in an amount equal to or less than 1 wt %, based on the total weight of the composition.
  • The compositions of the present invention can be used with a carrier or vehicle. The vehicle can be altered to be appropriate for the specific use of the composition without altering the beneficial lightening effects achieved by the use of the one or more active extracts set forth above. The vehicles that can be used in compositions of the present invention include, but are not limited to, water; vegetable oils; esters such as octyl palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dicapryl ether and dimethyl isosorbide; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, stearyl alcohol and behenyl alcohol; isoparaffins such as isooctane, isododecane and isohexadecane; silicone oils such as dimethicones and polysiloxanes; hydrocarbon oils such as mineral oil, petrolatum, isoeicosane and polyisobutene; polyols such as propylene glycol, glycerin, butylene glycol, pentylene glycol and hexylene glycol; or any combinations thereof.
  • Preferably, the vehicle is present in an amount about 50 wt % to about 99.8 wt % based on the total weight of the composition. More preferably, the vehicle is present in an amount about 80 wt % to about 99.5 wt % based on the total weight of the composition.
  • The present compositions may also include one or more of the following ingredients: anesthetic, anti-allergenic, antifungal, antimicrobial, anti-inflammatory agent, antioxidant, antiseptic, chelating agent, colorant, depigmenting agent, emollient, emulsifier, exfollient, film former, fragrance, humectant, insect repellent, lubricant, moisturizer, pharmaceutical agent, photostabilizing agent, preservative, skin protectant, skin penetration enhancer, sunscreen, stabilizer, surfactant, thickener, viscosity modifier, vitamin, or any combinations thereof. Preferably, these ingredients are present in an amount about 0.001 wt % to about 10 wt % based on the total weight of the composition.
  • The present compositions may also include skin whiteners. Some examples of such suitable skin whiteners include, but are not limited to, one or more of the following: ascorbyl glucoside, vitamin C, retinol and/or its derivatives, arbutin, bearberry extract, rumex crispus extract, milk proteins including hydrolyzed milk proteins, N,N,S-tris(carboxymethyl)cysteamine, oleanolic acids, perilla oils, placenta extract, saxifragia sarmentosa, perilla extract, juniperic acid, TDPA, ligusticum chiangxiong hort., asmunda japonica thunb., stellaria medica (L.) cyr., sedum sarmentosum bunge, ligusticum lucidum Ait., ilex purpurea hassk, emblica, apigenin, ascorbyl palmitol, carruba polyphenols, hesperitin, hydroquinone, inabata polyphenol, isoliquirtigenin, kaempherol-7-neohesperidose, L-mimosine, luteolin, oil-soluble licorice extract P-T(40), oxa acid, phenyl isothiocyanate, cococin, silymarin, T4CA, teterahydro curcumin, unitrienol, ursolic-oleanolic acid, UVA/URSI, or any combinations thereof.
  • The compositions of the present invention can be formulated in any suitable product form. Such product forms include, but are not limited to, aerosol spray, cream, dispersion, emulsion, foam, gel, liquid, lotion, mousse, ointment, patch, pomade, powder, pump spray, solid, solution, stick, and towelette.
  • The present compositions provide for products, especially cosmetic products that improve lightening of skin, nail, lips, and/or hair. Also, the present compositions can be formulated to deliver a consistent level of an active ingredient, or blend of ingredients, so that a desired cosmetic effect is achieved.
  • The following are examples of the present invention.
  • EXAMPLE 1
  • Melanosome Uptake Assay (Stenolama Chusana and Naringi Crenulata) was done as follows. Confluent cultures of B16 melanocytes produce moderate levels of melanosomes. However, to induce elevated melanosome production in this cell line, semi-confluent (60%) cultures of B16 cells were treated for approximately thirty-six (36) hours with normal growth medium supplemented with 10 mM ammonium chloride (final conc.). The medium was then aspirated and the hypermelanotic cells were washed (2×2 ml) with distilled water to provide a hypotonic stress to the cells. An aliquot (2 ml) of a hypotonic lysis solution (0.02% NP-40 in water) was added to each plate and the plates were incubated for approximately five (5) minutes at room temperature. Following verification of cell lysis using light microscopy, the cellular material from three (3) culture plates were pooled in a 15 ml conical tube and centrifuged (200×g) for 5 minutes to remove cellular debris. The resulting supernatant containing melanosomes was transferred to a clean 15 ml conical tube and centrifuged (850×g) for twenty (20) minutes. The resulting pellet containing the isolated melanosomes were resuspended in 1 ml of Phosphate Buffered Saline (PBS) and stored at 4° C. until used.
  • The treatment of keratinocytes with melanosomes was measured as follows. The normal human epidermal keratinocytes (NHEKs) (available from Clonetics, Inc.) were plated in the wells of 24-well plates at a density of 200,000 cells/well. Approximately twenty-four (24) hours later, the growth medium was replaced with 1 ml of the appropriate growth medium (i.e., DMEM/KGM-2) containing the melanosome preparation with or without additional treatment conditions. The cells were treated with different concentrations of perilla leaf extract (powder form or aqueous form). The cells were then returned to the incubator for approximately one and one-half (1.5) hours. For these studies, each well of keratinocytes was treated with the amount of melanosomes isolated from a single plate of B16 cells.
  • In some experiments, the 24-well plates of treated keratinocytes were centrifuged for 15 minutes at 1,000 rpm to facilitate the deposition of the melanosomes onto the surface membranes of the keratinocytes. The plates were then returned to the incubator for 1.25 hours.
  • For the analysis of melanosome uptake, the cells in each well of keratinocytes were rinsed (3×1 ml) with PBS, removed from the plate using trypsin/EDTA, and washed with PBS. To analyze the uptake of melanosomes by the keratinocytes, the internalized melanin was extracted from the cells according to a modified method of Bessou-Touya, S., et al. (Chimeric human epidermal reconstructs to study the role of melanocytes and keratinocytes in pigmentation and photoprotection. J. Invest. Dermatol., 111:1103-1108, 1998) and quantified spectrophoto-metrically by determining the melanin-specific absorbance at 405 nm.
  • The melanocytes synthesize melanin and deposits onto melanosomes. Visual manifestation of skin color is due to presence of melanin/melanosomes in keratinocytes. Melanosomes are taken up by keratinocytes and the rate of uptake, retention and processing of melanosomes in the keratinocytes is a key determinant of skin color. The internalized melanin value reflects the amount of melanin/melanosome uptake and retention by the keratinocytes. Thus, the lower internalized melanin values, particularly internalized melanin values that are less than the control with melanin, indicate that melanin uptake by the keratinocytes has been inhibited.
  • The results are as follows. At 0.5% volume/volume, Stenolama Chusana showed a 44% decrease in melanosome uptake as compared to the positive control. At 0.5% volume/volume, Naringi Crenulata showed a 39% decrease in melanosome uptake as compared to the positive control.
  • EXAMPLE 2
  • For B16 assay (Naringi Crenulata), the actives were tested in monolayer cell culture of B16 mouse melanoma cells. These cells constitutively produce melanin and are a model system for monitoring the inhibition of melanin synthesis. The cells were seeded into 96-well plates at 5×103 cells/well and culture attached for twenty-four (24) hours. The media were then replaced with fresh media containing plant extracts. Each active was applied to six (6) wells of B16 cells on 96-well plates to allow statistical analysis. The cells were dosed with medium alone as the negative control, or the test article for seven (7) days. The plates were read at 540 nM to detect melanin formation. An increase in absorbance at 540 nM reflects a higher melanin content in the well.
  • At 0.05% weight/volume, Naringi Crenulata showed a 61% decrease in pigmentation as compared to the positive control
  • EXAMPLE 3
  • For 14C-Dopa incorporation (Butea Frondosa), melanogenic activity was measured by measuring the radioactive melanin formed as 14C DOPA is converted to the acid insoluble melanin biopolymer in B16F10 melanoma cells. Cells were seeded into 24-well plates at a density of 2×104 cells per well and cultured attached for forty-eight (48) hours. The media were then replaced with fresh media containing plant extracts and 0.2 μCi of 14C DOPA. The cells were further incubated for 24 hours. After incubation, media were discarded and the cells were rinsed with PBS, lysed by adding 0.125 ml of 1N NaOH and incubated at 37° C. for 30 minutes, and then neutralized with 0.025 ml of 5N HCL. The resulting cell lysates were transferred into liquid scintillation vials and mixed with scintillation cocktail, and the radioactivity was determined by scintillation counter. A portion of the cell lysates was kept and the protein content was determined by Lowry method. The results were normalized to the amount of protein determined for each assay.
  • At 0.005% weight/volume, Butea frondosa showed a 22% decrease in 14C DOPA conversion as compared to the positive control.
  • EXAMPLE 4
  • Various natural plant extracts of the present invention were evaluated for inhibition of the TNF-alpha protein in an in vitro studies as described below.
  • TNF-alpha Inhibition Protocol
  • To test the efficacy of Stenolama chusana Ching., Naringi Crenulata, and Butea frondosa Roxb. for the inhibition of TNF-alpha production, an enzyme linked immunoassay (ELISA) commercially available from R&D Systems was employed.
  • This assay employed the quantitative sandwich enzyme immunoassay technique in which a monoclonal antibody specific for TNF-alpha has been pre-coated onto a microtiter plate. Culture supernatants from cells exposed to active materials were pipetted into separate wells. TNF-alpha in the supernatant was bound to the plate via the immobilized antibody. After several washes to remove unbound antibody, an enzyme-linked polyclonal antibody specific for TNF-alpha was added to each well. Following a wash to remove unbound antibody-enzyme reagent, a substrate solution was added to the wells. Color develops in proportion to the amount of TNF-alpha bound in the initial step. The results of the tests are provided in Table I.
    TABLE I
    Results of In Vitro Tests
    TNF-alpha
    Plant Extract Inhibition
    Stenolama chusana Ching. +++
    Naringi Crenulata +
    Butea frondosa Roxb. +++

    Legend:

    +, ++, +++, ++++ Significant inhibition (degree of inhibition quantified by number of plus signs)

    (0) No change
  • These in vitro studies show that the compositions of the present invention containing an extract of: Stenolama chusana Ching., Naringi Crenulata, and Butea frondosa Roxb. provide benefits to the skin by inhibiting TNF-alpha protein production, whereby the signs of subjective discomfort and/or irritation caused by cosmetic, pharmaceutical or dermatological products would be reduced, thus providing an aesthetic improvement in skin appearance.
  • EXAMPLE 5
  • Stenolama chusana ching. and Butea fondosa were evaluated in various biopsy studies in which the natural plant extract as set forth below was incorporated into a cosmetically suitable vehicle and applied to the volar forearm of a participant in the study, at a dose of 2 mg/cm2. The forearm area to which the extract preparation was applied was then covered with a semi-occlusive patch. This procedure was repeated for 3 weeks, 5 days per week. At the end of the treatment the sites were anesthetized with lidocaine and 2 mm punch biopsies were taken from the treated and one untreated control site. Biopsies were fixed in formalin, embedded in paraffin, sectioned, and stained for relevant endpoints.
  • For Stenolama chusana ching., 6 of 9 panelists showed increase in keratinocyte proliferation (visualized by the antibody to KI67), and 5 of 9 panelists showed increase in viable epidermal thickness.
  • For Butea frondosa provided, 5 of 8 panelists showed increase in keratinocyte proliferation (visualized by the antibody to KI67), and 5 of 8 panelists showed increase in viable epidermal thickness.
  • It should be understood that the foregoing description is only illustrative of the present invention. Various alternatives and modifications can be devised by those skilled in the art without departing from the invention. Accordingly, the present invention is intended to embrace all such alternatives, modifications and variances which fall within the scope of the appended claims.

Claims (27)

1. A composition for improving the aesthetic appearance of hair, skin, lips and/or nails, comprising:
an effective amount of at least one active extract selected from the group consisting of Butea frondosa, Naringi crenulata, Stenoloma chusana, and any combinations thereof.
2. The composition of claim 1, wherein the at least one active extract is present in an amount about 0.001 wt % to about 20 wt % based on the total weight of the composition.
3. The composition of claim 1, wherein the at least one active extract is present in an amount about 0.05 wt % to about 10 wt % based on the total weight of the composition.
4. The composition of claim 1, wherein the at least one active extract is present in an amount about 0.5 wt % to about 5 wt % based on the total weight of the composition.
5. The composition of claim 1, wherein the at least one active extract is present in an amount about 1 wt % or less based the total weight of the composition.
6. The composition of claim 1, wherein the composition is a topical composition suitable for application to hair, skin, lips, and/or nails.
7. The composition of claim 6, further comprising a cosmetically acceptable vehicle.
8. The composition of claim 1, wherein the skin or lips has reduced irritation and/or irritation is prevented when the composition is applied to skin or lips.
9. The composition of claim 1, wherein the composition is an oral composition.
10. The composition of claim 1, further comprising an effective amount of at least one additional extract selected from the group consisting of Azadirachta indica, Glycyrrhiza glabra linn., Morinda citrifolia, tomato glycolipid, and any combinations thereof.
11. The composition of claim 10, wherein the at least one additional extract is present in an amount about 0.05 wt % to about 10 wt % based on the total weight of the composition.
12. The composition of claim 11, wherein the at least one additional extract is present in an amount about 0.5 wt % to about 5 wt % based on the total weight of the composition.
13. The composition of claim 10, wherein the at least one active extract is topically applied to skin or lips to effect a reduction in or to prevent irritation or inflammation.
14. The composition of claim 1, wherein the at least one active extract is topically applied to skin or lips to effect a reduction in or to prevent irritation or inflammation.
15. A method of lightening hair, skin, lips and/or nails, comprising topically applying to the skin, hair, lips and/or nails an effective amount of the composition of claim 1.
16. The method of claim 15, wherein the at least one active extract is present in an amount about 0.001 wt % to about 20 wt % based on the total weight of the composition.
17. The method of claim 15, wherein the at least one active extract is present in an amount about 0.05 wt % to about 10 wt % based on the total weight of the composition.
18. The method of claim 15, wherein the at least one active extract is present in an amount about 0.5 wt % to about 5 wt % based on the total weight of the composition.
19. A method of lightening hair, skin, lips and/or nails, comprising orally ingesting an effective amount of the composition of claim 1.
20. A method of lightening hair, skin, lips and/or nails, comprising topically applying to the skin, hair and/or nails an effective amount of the composition of claim 10.
21. The method of claim 20, wherein the at least one additional extract is present in an amount about 0.05 wt % to about 10 wt % based on the total weight of the composition.
22. The method of claim 20, wherein the at least one additional extract is present in an amount about 0.5 wt % to about 5 wt % based on the total weight of the composition.
23. A method of lightening hair, skin, lips and/or nails, comprising orally ingesting an effective amount of the composition of claim 10.
24. A method for improving the aesthetic appearance of skin, lips, hair and/or nails comprising:
topically applying to the skin, lips, hair and/or nails an effective amount of at least one active extract selected from the group consisting of Butea frondosa, Naringi crenulata, Stenoloma chusana, and any combinations thereof.
25. The method of claim 24, wherein said effective amount is effective to provide an anti-aging benefit to the skin, lips, hair and/or nails.
26. The method of claim 24, wherein the effective amount is from about 0.001 wt % to about 20 wt % by weight of the composition, and is effective in the treatment of one or more of the following:
a) decreasing/preventing lines and wrinkles;
b) enhancing skin thickness; and
c) reducing skin discoloration.
27. The method of claim 24, wherein the effective amount is from about 0.001 wt % to about 20 wt % by weight of the composition, and is effective in the treatment of one or more of the following:
a) reducing or preventing loss of collagen;
b) improving skin firmness/plumpness;
c) improving skin texture;
d) decreasing/preventing lines and wrinkles;
e) improving skin tone;
f) enhancing skin thickness;
g) decreasing pore size;
h) reducing skin discoloration;
i) reducing acne;
j) reducing psoriasis;
k) reducing skin sensitivity; and
l) reducing warts.
US11/155,359 2002-12-17 2005-06-17 Use of active extracts to improve the appearance of skin, lips, hair and/or nails Abandoned US20060013782A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/155,359 US20060013782A1 (en) 2002-12-17 2005-06-17 Use of active extracts to improve the appearance of skin, lips, hair and/or nails

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/321,706 US7189419B2 (en) 2002-12-17 2002-12-17 Use of active extracts to lighten skin, lips, hair, and/or nails
PCT/US2003/039893 WO2004060285A2 (en) 2002-12-17 2003-12-16 Use of active extracts to improve the appearance of skin, lips, hair and/or nails
US11/155,359 US20060013782A1 (en) 2002-12-17 2005-06-17 Use of active extracts to improve the appearance of skin, lips, hair and/or nails

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/039893 Continuation-In-Part WO2004060285A2 (en) 2002-12-17 2003-12-16 Use of active extracts to improve the appearance of skin, lips, hair and/or nails

Publications (1)

Publication Number Publication Date
US20060013782A1 true US20060013782A1 (en) 2006-01-19

Family

ID=32507117

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/321,706 Expired - Fee Related US7189419B2 (en) 2002-12-17 2002-12-17 Use of active extracts to lighten skin, lips, hair, and/or nails
US11/155,359 Abandoned US20060013782A1 (en) 2002-12-17 2005-06-17 Use of active extracts to improve the appearance of skin, lips, hair and/or nails

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/321,706 Expired - Fee Related US7189419B2 (en) 2002-12-17 2002-12-17 Use of active extracts to lighten skin, lips, hair, and/or nails

Country Status (12)

Country Link
US (2) US7189419B2 (en)
EP (1) EP1572223B1 (en)
JP (1) JP4335152B2 (en)
CN (1) CN1694716A (en)
AT (1) ATE513539T1 (en)
AU (1) AU2003297126B2 (en)
BR (1) BR0314732A (en)
CA (2) CA2749289A1 (en)
HK (1) HK1083005A1 (en)
MX (1) MXPA05003230A (en)
PL (1) PL220112B1 (en)
WO (1) WO2004060285A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083397A1 (en) * 2010-01-05 2011-07-14 Himalaya Global Holdings Limited Herbal composition for skin disorders
CN102196813A (en) * 2008-10-24 2011-09-21 荷兰联合利华有限公司 Topical composition comprising extracts of A. indica and M. charantia or S. indicum
US20120197016A1 (en) * 2010-10-25 2012-08-02 The Procter & Gamble Company Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
US20120237623A1 (en) * 2009-12-04 2012-09-20 Avon Products, Inc. Topical Compositions Containing Derris Scandens Benth and a Method of Treating Skin
US8318215B1 (en) 2010-04-21 2012-11-27 Miriam Ryngler-Lewensztain Composition and method of preparing a tomato-based topical formulation for enhanced healing of burns, ultraviolet and radiation erythema
KR20170140790A (en) 2016-06-13 2017-12-21 성균관대학교산학협력단 Composition comprising extract or fraction of butea monosperma
US9999587B2 (en) 2010-06-30 2018-06-19 Avon Products, Inc. Compositions and methods for stimulation MAGP-1 to improve the appearance of skin
US10195136B2 (en) 2011-08-24 2019-02-05 Avon Products, Inc. Collagen and elastin stimulating compositions and uses thereof
WO2023167500A1 (en) * 2022-03-02 2023-09-07 방기정주식회사 Cosmetic composition for modified nail care and manufacturing method therefor

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126351A1 (en) * 2002-12-26 2004-07-01 Avon Products, Inc. Topical composition having natural skin anti-irritant ingredient and method of use
CN101076254B (en) * 2004-12-22 2012-10-31 雅芳产品公司 Method and composition for reducing the appearance of wrinkles
DE102005048778A1 (en) * 2005-10-10 2007-04-12 Beiersdorf Ag Cosmetic formulations to improve the appearance of the skin
DE102006047732A1 (en) * 2006-10-06 2008-04-10 Henkel Kgaa Means for the treatment of blond or bleached hair
EP2152231A1 (en) * 2007-06-11 2010-02-17 Chanel Parfums Beauté Use of active agents for stimulating the expression of fn3k and/or fn3k rp for combating ageing of the skin
JP2011520768A (en) * 2007-06-11 2011-07-21 シャネル パフュームズ ビューテ Cosmetic use of an active agent for stimulating the expression of FN3K and / or FN3KRP for improving the barrier function of the skin
US20110020302A1 (en) * 2009-07-23 2011-01-27 Professional Compounding Centers Of America, Ltd. Natural preservative blend
IN2014MN01949A (en) 2012-04-03 2015-07-10 Unilever Plc
CN106137811B (en) * 2015-04-03 2020-08-25 伽蓝(集团)股份有限公司 Plant extract composition and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858371A (en) * 1997-02-05 1999-01-12 Panacea Biotech Limited Pharmaceutical composition for the control and treatment of anorectal and colonic diseases
US6436417B1 (en) * 2001-06-25 2002-08-20 Blistex Inc. Acne treatment compositions
US20030064039A1 (en) * 2001-09-03 2003-04-03 Richard Kolodziej Foundation composition comprising interference pigments
US20040067245A1 (en) * 2000-12-20 2004-04-08 Harish Mahalingam Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US20040216344A1 (en) * 2001-05-21 2004-11-04 Bateman Roger Christopher Display device

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745186A (en) 1985-03-08 1988-05-17 Plant Cell Research Institute, Inc. 2,3,4-triacylhexoses and mixtures thereof
HU214255B (en) 1992-12-23 1998-03-02 Rohm And Haas Co. A method for producing azadirachtin
JPH0725742A (en) 1993-07-15 1995-01-27 Kao Corp Fair-skinning cosmetic
JP2884466B2 (en) 1993-12-27 1999-04-19 長瀬産業株式会社 Perilla extract, method for producing the same, and whitening cosmetic containing the same
IL109012A (en) * 1994-03-17 1998-09-24 Fischer Pharma Ltd Skin whitening composition comprising glycyrrhyza glabra and hydroxy acids
CN1059333C (en) * 1996-09-20 2000-12-13 胡长意 Chinese patent drug for various cancers and tumors
US5756099A (en) 1996-12-14 1998-05-26 Jewel Simpson Natural organic tanning sunscreen compositions and methods of treatment, to reduce the risk of skin cancer caused by sunlight and ultraviolet radiation (UVA and UVB)
JPH10265322A (en) 1997-03-19 1998-10-06 Shiseido Co Ltd Skin preparation for external use
US6248309B1 (en) 1997-04-04 2001-06-19 Optiva Corporation Gums containing antimicrobial agents
US5980904A (en) 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
US6673377B1 (en) 1999-08-27 2004-01-06 Cheil Jedang Corporation Extracts derived from Pueraria mirifica, Butea superba and/or Mucuna collettii and extraction thereof
US6214351B1 (en) 1999-08-27 2001-04-10 Morinda, Inc. Morinda citrifolia oil
JP4015792B2 (en) 1999-12-10 2007-11-28 株式会社コーセー Whitening agent and external preparation for skin containing it as an active ingredient
JP2001181173A (en) 1999-12-27 2001-07-03 Kose Corp Bleaching preparation for external use
FR2815907B1 (en) 2000-11-02 2002-12-13 Oreal SYSTEM FOR TRANSFERRING A COLORED PATTERN ON THE SKIN AND USES THEREOF
FR2815906A1 (en) 2000-11-02 2002-05-03 Oreal SYSTEM FOR TRANSFERRING A COLORED PATTERN ON THE SKIN AND USES THEREOF
FR2816832B1 (en) 2000-11-23 2003-09-26 Oreal COSMETIC COMPOSITION COMPRISING INTERFERENTIAL PARTICLES AND A COLORING MATERIAL
US6387370B1 (en) 2001-01-19 2002-05-14 A. Glenn Braswell Compositions containing extracts of Morinda citrifolia, red wine, prune, blueberry, pomegranate, apple and enzyme mixture
JP2002308724A (en) * 2001-03-29 2002-10-23 Council Scient Ind Res Safe, eco-friendly, health rpotective herbal color and aroma useful for cosmaceutical application
JP2003113031A (en) * 2001-09-28 2003-04-18 Ts Aasu:Kk Skin care preparation
US7435707B2 (en) * 2002-05-23 2008-10-14 The Lubrizol Corporation Oil-in-water emulsions and a method of producing
US20040126344A1 (en) * 2002-12-26 2004-07-01 Avon Products, Inc. Compositions having glycolipid to lighten skin and alter post-inflammatory hyperpigmentation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858371A (en) * 1997-02-05 1999-01-12 Panacea Biotech Limited Pharmaceutical composition for the control and treatment of anorectal and colonic diseases
US20040067245A1 (en) * 2000-12-20 2004-04-08 Harish Mahalingam Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US20040216344A1 (en) * 2001-05-21 2004-11-04 Bateman Roger Christopher Display device
US6436417B1 (en) * 2001-06-25 2002-08-20 Blistex Inc. Acne treatment compositions
US20030064039A1 (en) * 2001-09-03 2003-04-03 Richard Kolodziej Foundation composition comprising interference pigments

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102196813A (en) * 2008-10-24 2011-09-21 荷兰联合利华有限公司 Topical composition comprising extracts of A. indica and M. charantia or S. indicum
US20120237623A1 (en) * 2009-12-04 2012-09-20 Avon Products, Inc. Topical Compositions Containing Derris Scandens Benth and a Method of Treating Skin
WO2011083397A1 (en) * 2010-01-05 2011-07-14 Himalaya Global Holdings Limited Herbal composition for skin disorders
US8318215B1 (en) 2010-04-21 2012-11-27 Miriam Ryngler-Lewensztain Composition and method of preparing a tomato-based topical formulation for enhanced healing of burns, ultraviolet and radiation erythema
US9999587B2 (en) 2010-06-30 2018-06-19 Avon Products, Inc. Compositions and methods for stimulation MAGP-1 to improve the appearance of skin
US10849840B2 (en) 2010-06-30 2020-12-01 New Avon Llc Compositions and methods for stimulation MAGP-1 to improve the appearance of skin
US20120197016A1 (en) * 2010-10-25 2012-08-02 The Procter & Gamble Company Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
US10267796B2 (en) * 2010-10-25 2019-04-23 The Procter & Gamble Company Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
US10195136B2 (en) 2011-08-24 2019-02-05 Avon Products, Inc. Collagen and elastin stimulating compositions and uses thereof
KR20170140790A (en) 2016-06-13 2017-12-21 성균관대학교산학협력단 Composition comprising extract or fraction of butea monosperma
WO2023167500A1 (en) * 2022-03-02 2023-09-07 방기정주식회사 Cosmetic composition for modified nail care and manufacturing method therefor

Also Published As

Publication number Publication date
CN1694716A (en) 2005-11-09
ATE513539T1 (en) 2011-07-15
EP1572223A2 (en) 2005-09-14
CA2749289A1 (en) 2004-07-22
BR0314732A (en) 2005-07-26
PL220112B1 (en) 2015-08-31
PL377205A1 (en) 2006-01-23
AU2003297126A1 (en) 2004-07-29
US7189419B2 (en) 2007-03-13
CA2500378A1 (en) 2004-07-22
WO2004060285A2 (en) 2004-07-22
EP1572223B1 (en) 2011-06-22
CA2500378C (en) 2011-10-25
WO2004060285A3 (en) 2005-04-28
HK1083005A1 (en) 2006-06-23
JP2006514055A (en) 2006-04-27
AU2003297126B2 (en) 2007-04-19
EP1572223A4 (en) 2007-03-21
US20040115146A1 (en) 2004-06-17
MXPA05003230A (en) 2005-07-05
JP4335152B2 (en) 2009-09-30

Similar Documents

Publication Publication Date Title
US20060013782A1 (en) Use of active extracts to improve the appearance of skin, lips, hair and/or nails
EP1441686B1 (en) Topical cosmetic composition with skin rejuvenation benefits
US9925136B2 (en) Methods of reducing signs of skin aging using compositions comprising ampelopsis grossedentata and albizia julibrissin extracts
KR20100010316A (en) Cosmetic composition for preventing skin aging
AU2003297226B2 (en) Topical compositions having a natural ingredient and method of use
US20220305071A1 (en) Composition comprising prunus persica extract
KR101180258B1 (en) A skin-care agent containing Ophioglossum vulgatum extracts using microbial fermentation
US20040126344A1 (en) Compositions having glycolipid to lighten skin and alter post-inflammatory hyperpigmentation
KR100829729B1 (en) Skin agent composition containing an extract of ophiglossum vulgatum
KR20160096272A (en) A skin-care agent containing Mesembryanthemum crystallinum L. fermentation extract using yeast
KR100564107B1 (en) Cosmetic composition comprising plant extract having anti-aging effect
KR100553810B1 (en) A composition containing Plantago asiatica Linne extract for skin external application
TWI352602B (en) Use of active extracts to improve the appearance o
KR20240001075A (en) Skin whitening composition containing pumpkin's tendril extract

Legal Events

Date Code Title Description
AS Assignment

Owner name: AVON PRODUCTS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAHALINGAM, HARISH;JONES, BRIAN C.;MCCAIN, NICOLE;AND OTHERS;REEL/FRAME:017013/0882;SIGNING DATES FROM 20050720 TO 20050819

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION